AVTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AVTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Avalo Therapeutics's tax expense for the months ended in Mar. 2024 was $0.01 Mil. Its tax expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.01 Mil.
The historical data trend for Avalo Therapeutics's Tax Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalo Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Tax Expense | Get a 7-Day Free Trial | 0.28 | -2.79 | -0.20 | 0.03 | 0.01 |
Avalo Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Tax Expense | Get a 7-Day Free Trial | 0.01 | 0.01 | 0.01 | -0.01 | 0.01 |
Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.
Tax Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalo Therapeutics (NAS:AVTX) Tax Expense Explanation
In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.
Thank you for viewing the detailed overview of Avalo Therapeutics's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
Armistice Capital Master Fund Ltd. | director, 10 percent owner | C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Caissa Capital Management Ltd. | 10 percent owner | PALM GROVE HOUSE, WICKHAMS CAY 1 ROAD TOWN, TORTOLA D8 VG1110 |
Christopher Ryan Sullivan | officer: Interim CFO | C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Garry Arthur Neil | officer: Chief Medical Officer | 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104 |
Mitchell Chan | director | C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG MD 20878 |
Stephen Smolinski | officer: Chief Commercial Officer | C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472 |
Magnus Persson | director | 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Joseph M Miller | director | C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Gilla Kaplan | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
June Sherie Almenoff | director | C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019 |
Schond L. Greenway | officer: CFO & Treasurer | C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850 |
H Jeffrey Wilkins | officer: Chief Medical Officer | 600 LEE ROAD, SUITE 100, WAYNE PA 19087 |
Harrell James Archie Jr | officer: Chief Commercial Officer | C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Illya Keith Maher | director | C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022 |
Steven Boyd | director, 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By Marketwired • 07-06-2023
By Marketwired • 06-26-2023
By sperokesalga sperokesalga • 05-15-2023
By Marketwired • 09-26-2023
By GuruFocusNews GuruFocusNews • 06-27-2022
By Stock market mentor Stock market mentor • 01-17-2023
By Ds*** Ds*** • 09-01-2022
By GuruFocusNews GuruFocusNews • 06-26-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
By GuruFocus Research • 11-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.